Kyounghyun Kim, Ph.D. - Publications

Affiliations: 
2004 Texas A & M University, College Station, TX, United States 
Area:
Molecular Biology, Oncology, Toxicology

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Park YY, Yun Jung S, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Bae Kim S, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. PMID 31063534 DOI: 10.1093/carcin/bgz062  0.6
2019 Khanal T, Leung YK, Jiang W, Timchenko N, Ho SM, Kim K. NR2E3 is a key component in p53 activation by regulating a long noncoding RNA DINO in acute liver injuries. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201801881RR. PMID 30991008 DOI: 10.1096/fj.201801881RR  0.44
2017 Khanal T, Choi K, Leung YK, Wang J, Kim D, Janakiram V, Cho SG, Puga A, Ho SM, Kim K. Loss of NR2E3 represses AHR by LSD1 reprogramming, is associated with poor prognosis in liver cancer. Scientific Reports. 7: 10662. PMID 28878246 DOI: 10.1038/s41598-017-11106-2  0.6
2016 Hedrick E, Cheng Y, Jin UH, Kim K, Safe S. Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cells. Oncotarget. PMID 26967243 DOI: 10.18632/oncotarget.7925  1
2015 Gandhy SU, Imanirad P, Jin UH, Nair V, Hedrick E, Cheng Y, Corton JC, Kim K, Safe S. Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC. Oncotarget. PMID 26317792 DOI: 10.18632/oncotarget.4560  0.68
2014 Yang WS, Chadalapaka G, Cho SG, Lee SO, Jin UH, Jutooru I, Choi K, Leung YK, Ho SM, Safe S, Kim K. The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis. Neoplasia (New York, N.Y.). 16: 1059-69. PMID 25499219 DOI: 10.1016/j.neo.2014.09.011  1
2014 Zhang Z, Kim K, Li X, Moreno M, Sharp T, Goodheart MJ, Safe S, Dupuy AJ, Amendt BA. MicroRNA-26b represses colon cancer cell proliferation by inhibiting lymphoid enhancer factor 1 expression. Molecular Cancer Therapeutics. 13: 1942-51. PMID 24785257 DOI: 10.1158/1535-7163.MCT-13-1000  0.68
2014 Jutooru I, Guthrie AS, Chadalapaka G, Pathi S, Kim K, Burghardt R, Jin UH, Safe S. Mechanism of action of phenethylisothiocyanate and other reactive oxygen species-inducing anticancer agents. Molecular and Cellular Biology. 34: 2382-95. PMID 24732804 DOI: 10.1128/MCB.01602-13  0.68
2013 Chadalapaka G, Jutooru I, Sreevalsan S, Pathi S, Kim K, Chen C, Crose L, Linardic C, Safe S. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors. International Journal of Cancer. 132: 795-806. PMID 22815231 DOI: 10.1002/ijc.27730  0.68
2013 Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 32: 1616-25. PMID 22614017 DOI: 10.1038/onc.2012.193  1
2012 Gandhy SU, Kim K, Larsen L, Rosengren RJ, Safe S. Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. Bmc Cancer. 12: 564. PMID 23194063 DOI: 10.1186/1471-2407-12-564  1
2012 Kim K, Chadalapaka G, Pathi SS, Jin UH, Lee JS, Park YY, Cho SG, Chintharlapalli S, Safe S. Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. Molecular Cancer Therapeutics. 11: 1852-62. PMID 22752225 DOI: 10.1158/1535-7163.MCT-12-0181  0.68
2012 Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 33: 1843-53. PMID 22581827 DOI: 10.1093/carcin/bgs167  0.68
2012 Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Molecular Cancer Therapeutics. 11: 1421-31. PMID 22553354 DOI: 10.1158/1535-7163.MCT-12-0026  1
2012 Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, Lim JY, Li J, Lu Y, Gonzalez-Angulo AM, Jeong W, Mills GB, Safe S, Lee JS. Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. Embo Molecular Medicine. 4: 52-67. PMID 22174013 DOI: 10.1002/emmm.201100187  1
2012 Lee SO, Andey T, Jin UH, Kim K, Singh M, Sachdeva M, Safe S. The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53. Oncogene. 31: 3265-76. PMID 22081070 DOI: 10.1038/onc.2011.504  1
2012 Zhang S, Kim K, Jin UH, Pfent C, Cao H, Amendt B, Liu X, Wilson-Robles H, Safe S. Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells. Molecular Cancer Therapeutics. 11: 108-18. PMID 22034498 DOI: 10.1158/1535-7163.MCT-11-0548  1
2012 Kim K, Chadalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA, Park YY, Lee JS, Safe S. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene. 31: 1034-44. PMID 21765466 DOI: 10.1038/onc.2011.296  1
2011 Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, Lee JS, Mills GB, Cho JY. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. Plos One. 6: e24662. PMID 21931799 DOI: 10.1371/journal.pone.0024662  0.6
2011 Yoon K, Lee SO, Cho SD, Kim K, Khan S, Safe S. Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors. Carcinogenesis. 32: 836-42. PMID 21362629 DOI: 10.1093/carcin/bgr040  1
2011 Kim K, Burghardt R, Barhoumi R, Lee SO, Liu X, Safe S. MDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cells. Journal of Molecular Endocrinology. 46: 67-79. PMID 21169420 DOI: 10.1677/JME-10-0110  1
2010 Lee SO, Abdelrahim M, Yoon K, Chintharlapalli S, Papineni S, Kim K, Wang H, Safe S. Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Research. 70: 6824-36. PMID 20660371 DOI: 10.1158/0008-5472.CAN-10-1992  1
2010 Li X, Mertens-Talcott SU, Zhang S, Kim K, Ball J, Safe S. MicroRNA-27a Indirectly Regulates Estrogen Receptor {alpha} Expression and Hormone Responsiveness in MCF-7 Breast Cancer Cells. Endocrinology. 151: 2462-73. PMID 20382698 DOI: 10.1210/en.2009-1150  1
2008 Safe S, Kim K, Kim K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. Journal of Molecular Endocrinology. 41: 263-75. PMID 18772268 DOI: 10.1677/JME-08-0103  1
2008 Wu F, Xu R, Kim K, Martin J, Safe S. In vivo profiling of estrogen receptor/specificity protein-dependent transactivation. Endocrinology. 149: 5696-705. PMID 18635651 DOI: 10.1210/en.2008-0720  1
2007 Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (New York, N.Y.). 317: 121-4. PMID 17615358 DOI: 10.1126/science.1140485  0.48
2006 Khan S, Barhoumi R, Burghardt R, Liu S, Kim K, Safe S. Molecular mechanism of inhibitory aryl hydrocarbon receptor-estrogen receptor/Sp1 cross talk in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 20: 2199-214. PMID 16675542 DOI: 10.1210/me.2006-0100  1
2006 Abdelrahim M, Ariazi E, Kim K, Khan S, Barhoumi R, Burghardt R, Liu S, Hill D, Finnell R, Wlodarczyk B, Jordan VC, Safe S. 3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha. Cancer Research. 66: 2459-67. PMID 16489053 DOI: 10.1158/0008-5472.CAN-05-3132  1
2005 Kim K, Barhoumi R, Burghardt R, Safe S. Analysis of estrogen receptor alpha-Sp1 interactions in breast cancer cells by fluorescence resonance energy transfer. Molecular Endocrinology (Baltimore, Md.). 19: 843-54. PMID 15637147 DOI: 10.1210/me.2004-0326  1
2005 Lee JE, Kim K, Sacchettini JC, Smith CV, Safe S. DRIP150 coactivation of estrogen receptor alpha in ZR-75 breast cancer cells is independent of LXXLL motifs. The Journal of Biological Chemistry. 280: 8819-30. PMID 15625066 DOI: 10.1074/jbc.M413184200  1
2004 Safe S, Kim K. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Progress in Nucleic Acid Research and Molecular Biology. 77: 1-36. PMID 15196889 DOI: 10.1016/S0079-6603(04)77001-4  1
2003 Kim K, Thu N, Saville B, Safe S. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 17: 804-17. PMID 12576490 DOI: 10.1210/me.2002-0406  1
2001 Porter W, Wang F, Duan R, Qin C, Castro-Rivera E, Kim K, Safe S. Transcriptional activation of heat shock protein 27 gene expression by 17beta-estradiol and modulation by antiestrogens and aryl hydrocarbon receptor agonists. Journal of Molecular Endocrinology. 26: 31-42. PMID 11174852  1
Show low-probability matches.